Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Also Known As:
Networked: 16308 relevant articles (571 outcomes, 1324 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Fibrosis (Cirrhosis)
2. Osteoporosis
3. Infection
4. Dyspareunia
5. Body Weight (Weight, Body)


1. Alzheimer's Disease Neuroimaging Initiative: 67 articles (01/2016 - 07/2008)
2. Jack, Clifford R: 53 articles (01/2016 - 07/2003)
3. Scheltens, Philip: 48 articles (11/2015 - 03/2002)
4. Powers, Scott K: 44 articles (11/2015 - 11/2002)
5. Weiner, Michael W: 43 articles (01/2016 - 05/2006)
6. Barkhof, Frederik: 39 articles (11/2015 - 08/2002)
7. Thompson, Paul M: 30 articles (01/2016 - 05/2008)
8. Petersen, Ronald C: 30 articles (12/2015 - 06/2005)
9. Trojanowski, John Q: 29 articles (12/2015 - 11/2003)
10. Barkhof, F: 28 articles (04/2015 - 11/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Atrophy:
1. Estrogens (Estrogen)FDA Link
2. Retinaldehyde (Retinal)IBA
3. Estradiol (Estrace)FDA LinkGeneric
4. Testosterone (Sustanon)FDA Link
5. Adrenal Cortex Hormones (Corticosteroids)IBA
6. Insulin (Novolin)FDA Link
7. HormonesIBA
8. Dehydroepiandrosterone (DHEA)IBA
9. Glutamine (L-Glutamine)FDA Link
10. Vaginal Creams, Foams, and Jellies (Vaginal Tablet)IBA

Therapies and Procedures

1. Transplants (Transplant)
02/01/2013 - "In the treatment of jaw bone atrophies, autologus bone is still considered the gold standard because of its excellent osteoconductive, osteoinductive, and osteogenetic proprieties and lack of immunogenicity, which allow better graft integration and stability. "
12/01/2008 - "Nevertheless, certain issues seem to have cleared up: ASCT should be used early, during the inflammatory phase of the disease; very high-intensity pre-transplant conditioning regimens increase toxicity but do not seem to increase efficacy compared to intermediate-intensity regimens; the results are dramatic and life-saving in resistant, so-called "malignant" cases; ASCT does not only cause debulking of autoreactive clones but it also brings about qualitative immunological changes that might eventually establish immunologic self-tolerance; the progression of brain atrophy appears to slow down with time; with the implementation of proper patient-selection criteria, the risks of morbidity and mortality can be minimized."
08/01/2001 - "However, rats that received intrastriatal fetal-striatum grafts shortly after the lesion and were killed 12 months later showed a significant reduction in cortical atrophy, and a large number of labeled corticostriatal fibers surrounding and innervating the graft. "
01/01/1997 - "A widely held tenet in the reconstructive surgery literature is that muscle transplants undergo significant postoperative atrophy, contributing to progressive improvement in appearance of the reconstruction. "
08/01/1992 - "The weight of the transplanted left lobes was significantly greater than the untransplanted right lobes of the groups at 3 days (p less than 0.01) and at 7 days (p less than 0.05) after end-to-side PCS compared with control animals, indicating that liver atrophy was prevented in the islet-transplanted lobes but not in those lobes without a transplant. "
2. Denervation
3. Transplantation (Transplant Recipients)
4. Aftercare (After-Treatment)
5. Hormone Replacement Therapy (Therapy, Hormone Replacement)